A Phase I, Open-Label Study of D-0502 Single
Agent and D-0502 in Combination with Palbociclib in Postmenopausal Women With Advanced or Metastatic ER- Positive and HER2-Negative Breast Cancer, NCT03471663
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
This is a phase I, open-label study of D-0502 single agent and D-0502 in combination with standard dose of palbociclib to assess the safety and tolerability, identify an MTD, and/or RP2D, evaluate the PK properties and evaluate preliminary anti-tumor activities in women with advanced or metastatic ER-positive, HER2-negative breast cancer.
MORE DETAILS ON THIS TRIAL
17194 / NCT03471663 / Call PM 4-26-2018